What are RYTM's recent SEC filings?
Rhythm Pharmaceuticals filed its quarterly 10-Q report for the period ending September 30, 2026, reporting 69,330,906 shares of common stock outstanding.
View full filing details →Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, up 29% sequentially, driven by strong U.S. launch momentum for IMCIVREE in acquired hypothalamic obesity with over 700 patient start forms. The company also announced a restructured bivamelagon royalty agreement with LG Chem and secured a five-year term loan facility providing access to up to $750 million.
View full filing details →A Schedule 13G was filed regarding Rhythm Pharmaceuticals, Inc. (RYTM), indicating a passive ownership position by an institutional or other holder. The filing text provided does not disclose the holder's name, ownership percentage, or share count.
View full filing details →Has RYTM ever done a stock split?
No stock splits are recorded for RYTM.
What is RYTM's share float?
Get Real-Time RYTM Intelligence
SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.
Try SEPT X-Ray Free